{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:42:05Z","timestamp":1792399325007,"version":"4.4.0"},"reference-count":103,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/doi.org\/10.37349\/Open_Exploration_Crossmark_Policy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Multikinase inhibitors (MKIs) and highly selective tyrosine kinase inhibitors (HS-TKIs) positively impact the progression-free survival (PFS) of locally advanced and metastatic thyroid cancer cases. Moreover, disease-specific survival (DSS) and overall survival (OS) improvements were observed in some instances, suggesting a general benefit in disease control. In advanced and metastatic thyroid cancers, other conventional treatments are often ineffective when surgery cannot be performed due to the extension of the disease and\/or the invasion of vital neck structures (such as the larynx, trachea, esophagus, recurrent laryngeal nerve, and carotid artery). In these cases, systemic treatments with MKIs and HS-TKIs have recently been evaluated for their potential to block tumor growth and reduce tumor size to make surgery possible or improve the control of metastatic disease. The study aimed to evaluate the performance of these systemic drugs in the neoadjuvant treatment of thyroid cancer patients, focusing on their efficacy according to the different histology.<\/jats:p>","DOI":"10.37349\/etat.2025.1002291","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T01:28:20Z","timestamp":1739496500000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer"],"prefix":"10.37349","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7723-7020","authenticated-orcid":false,"given":"Laura","family":"Valerio","sequence":"first","affiliation":[{"name":"Department of Medical, Surgical and Neurological Sciences, Unit of Endocrinology, Siena University Hospital, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4263-4717","authenticated-orcid":false,"given":"Antonio","family":"Matrone","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21850","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Cabanillas ME, Ryder M, Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocr Rev. 2019;40:1573\u2013604. [PMID: 31322645 PMCID: PMC7341904 DOI: 10.1210\/er.2019-00007]","DOI":"10.1210\/er.2019-00007"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, et al. Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. Best Pract Res Clin Endocrinol Metab. 2017;31:319\u201334. [PMID: 28911728 DOI: 10.1016\/j.beem.2017.06.001]","DOI":"10.1016\/j.beem.2017.06.001"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Valerio L, Pieruzzi L, Giani C, Agate L, Bottici V, Lorusso L, et al. Targeted Therapy in Thyroid Cancer: State of the Art. Clin Oncol (R Coll Radiol). 2017;29:316\u201324. [PMID: 28318881 DOI: 10.1016\/j.clon.2017.02.009]","DOI":"10.1016\/j.clon.2017.02.009"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Ark N, Zemo S, Nolen D, Holsinger FC, Weber RS. Management of locally invasive well-differentiated thyroid cancer. Surg Oncol Clin N Am. 2008;17:145\u201355, ix. [PMID: 18177804 DOI: 10.1016\/j.soc.2007.10.009]","DOI":"10.1016\/j.soc.2007.10.009"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621\u201330. [PMID: 25671254 DOI: 10.1056\/NEJMoa1406470]","DOI":"10.1056\/nejmoa1406470"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al.; DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319\u201328. [PMID: 24768112 PMCID: PMC4366116 DOI: 10.1016\/S0140-6736(14)60421-9]","DOI":"10.1016\/s0140-6736(14)60421-9"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Brose MS, Robinson BG, Sherman SI, Jarzab B, Lin CC, Vaisman F, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer. 2022;128:4203\u201312. [PMID: 36259380 PMCID: PMC10092751 DOI: 10.1002\/cncr.34493]","DOI":"10.1002\/cncr.34493"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Filetti S, Durante C, Hartl DM, Leboulleux S, Locati LD, Newbold K, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022;33:674\u201384. [PMID: 35491008 DOI: 10.1016\/j.annonc.2022.04.009]","DOI":"10.1016\/j.annonc.2022.04.009"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol. 2022;23:1261\u201373. [PMID: 36108661 PMCID: PMC11702314 DOI: 10.1016\/S1470-2045(22)00541-1]","DOI":"10.1016\/s1470-2045(22)00541-1"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Chu YH, Dias-Santagata D, Farahani AA, Boyraz B, Faquin WC, Nos\u00e9 V, et al. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). Mod Pathol. 2020;33:2186\u201397. [PMID: 32457407 PMCID: PMC7584778 DOI: 10.1038\/s41379-020-0574-4]","DOI":"10.1038\/s41379-020-0574-4"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340. [PMID: 32105622 PMCID: PMC7497841 DOI: 10.1016\/S1470-2045(19)30856-3]","DOI":"10.1016\/s1470-2045(19)30856-3"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study. Lancet Oncol. 2018;19:705\u201314. [PMID: 29606586 PMCID: PMC5949072 DOI: 10.1016\/S1470-2045(18)30119-0]","DOI":"10.1016\/s1470-2045(18)30119-0"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378:731\u20139. [PMID: 29466156 PMCID: PMC5857389 DOI: 10.1056\/NEJMoa1714448]","DOI":"10.1056\/nejmoa1714448"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Al-Salama ZT, Keam SJ. Entrectinib: First Global Approval. Drugs. 2019;79:1477\u201383. [PMID: 31372957 DOI: 10.1007\/s40265-019-01177-y]","DOI":"10.1007\/s40265-019-01177-y"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Germani MM, Boccaccio C, Matrone A, Molinaro E, Al\u00ec G, Giordano M, et al. A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma. Oncologist. 2024;29:84\u20138. [PMID: 38037189 PMCID: PMC10769806 DOI: 10.1093\/oncolo\/oyad310]","DOI":"10.1093\/oncolo\/oyad310"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Willis C, Au T, Hejazi A, Griswold C, Schabath MB, Thompson J, et al. Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers. J Manag Care Spec Pharm. 2024;30:672\u201383. [PMID: 38950155 PMCID: PMC11217863 DOI: 10.18553\/jmcp.2024.30.7.672]","DOI":"10.18553\/jmcp.2024.30.7.672"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Chawla N, Bui NQ, Seetharam M. Evolving role of entrectinib in treatment of NTRK-positive tumors. Future Oncol. 2021;17:2835\u201346. [PMID: 33896226 DOI: 10.2217\/fon-2020-0936]","DOI":"10.2217\/fon-2020-0936"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Ricarte-Filho JC, Halada S, O\u2019Neill A, Casado-Medrano V, Laetsch TW, Franco AT, et al. The clinical aspect of NTRK-fusions in pediatric papillary thyroid cancer. Cancer Genet. 2022;262\u2013263:57\u201363. [PMID: 35092884 PMCID: PMC8931989 DOI: 10.1016\/j.cancergen.2022.01.002]","DOI":"10.1016\/j.cancergen.2022.01.002"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Scott LJ. Larotrectinib: First Global Approval. Drugs. 2019;79:201\u20136. [PMID: 30635837 DOI: 10.1007\/s40265-018-1044-x]","DOI":"10.1007\/s40265-018-1044-x"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Peng X, Lei J, Li Z, Zhang K. Case report: Visibly curative effect of dabrafenib and trametinib on advanced thyroid carcinoma in 2 patients. Front Oncol. 2023;12:1099268. [PMID: 36686787 PMCID: PMC9850096 DOI: 10.3389\/fonc.2022.1099268]","DOI":"10.3389\/fonc.2022.1099268"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Jafri S, Yaqub A. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib. Cureus. 2021;13:e17488. [PMID: 34595070 PMCID: PMC8465644 DOI: 10.7759\/cureus.17488]","DOI":"10.7759\/cureus.17488"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, et al. A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer. Clin Cancer Res. 2023;29:2401\u20139. [PMID: 37074727 DOI: 10.1158\/1078-0432.CCR-23-0046]","DOI":"10.1158\/1078-0432.ccr-23-0046"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid. 2021;31:1076\u201385. [PMID: 33509020 PMCID: PMC8290324 DOI: 10.1089\/thy.2020.0322]","DOI":"10.1089\/thy.2020.0322"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30:1856\u201383. [PMID: 31549998 DOI: 10.1093\/annonc\/mdz400]","DOI":"10.1093\/annonc\/mdz400"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Luongo C, Porcelli T, Sessa F, De Stefano MA, Scavuzzo F, Damiano V, et al. Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report. Curr Oncol. 2021;28:5401\u20137. [PMID: 34940089 PMCID: PMC8700686 DOI: 10.3390\/curroncol28060450]","DOI":"10.3390\/curroncol28060450"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Boudin L, Morvan JB, Thariat J, M\u00e9tivier D, Marcy PY, Delarbre D. Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma. Curr Oncol. 2022;29:7718\u201331. [PMID: 36290887 PMCID: PMC9601195 DOI: 10.3390\/curroncol29100610]","DOI":"10.3390\/curroncol29100610"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Maurer E, Eilsberger F, W\u00e4chter S, Riera Knorrenschild J, Pehl A, Holzer K, et al. Mutation-based, short-term \u201cneoadjuvant\u201d treatment allows resectability in stage IVB and C anaplastic thyroid cancer. Eur Arch Otorhinolaryngol. 2023;280:1509\u201318. [PMID: 36637521 PMCID: PMC9899736 DOI: 10.1007\/s00405-023-07827-y]","DOI":"10.1007\/s00405-023-07827-y"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Locati LD, Colombo E, Dedecjus M, de la Fouchardi\u00e8re C, Sents W, Bongiovanni M, et al. Current picture of anaplastic thyroid cancer patients\u2019 care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups. Eur J Cancer. 2023;180:146\u201354. [PMID: 36599182 DOI: 10.1016\/j.ejca.2022.12.002]","DOI":"10.1016\/j.ejca.2022.12.002"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr, et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021;31:337\u201386. [PMID: 33728999 PMCID: PMC8349723 DOI: 10.1089\/thy.2020.0944]","DOI":"10.1089\/thy.2020.0944"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33:406\u201315. [PMID: 35026411 PMCID: PMC9338780 DOI: 10.1016\/j.annonc.2021.12.014]","DOI":"10.1016\/j.annonc.2021.12.014"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, et al. Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2018;2:PO.18.00173. [PMID: 35135166 PMCID: PMC9797231 DOI: 10.1200\/PO.18.00173]","DOI":"10.1200\/po.18.00173"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Bueno F, Smulever A, Califano I, Guerra J, Del Grecco A, Carrera JM, et al. Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience. Endocrine. 2023;80:134\u201341. [PMID: 36617605 PMCID: PMC9838471 DOI: 10.1007\/s12020-022-03295-2]","DOI":"10.1007\/s12020-022-03295-2"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022;186:631\u201343. [PMID: 35333737 PMCID: PMC9066591 DOI: 10.1530\/EJE-21-1259]","DOI":"10.1530\/eje-21-1259"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Dam\u00e1sio I, Sim\u00f5es-Pereira J, Donato S, Horta M, Cavaco BM, Rito M, et al. Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report. Eur Thyroid J. 2022;12:e220179. [PMID: 36378538 PMCID: PMC9874958 DOI: 10.1530\/ETJ-22-0179]","DOI":"10.1530\/etj-22-0179"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134\u201341. [PMID: 22025146 PMCID: PMC3675689 DOI: 10.1200\/JCO.2011.35.5040]","DOI":"10.1200\/jco.2010.28.15_suppl.5503"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP, Sch\u00f6ffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639\u201346. [PMID: 24002501 PMCID: PMC4164813 DOI: 10.1200\/JCO.2012.48.4659]","DOI":"10.1200\/jco.2012.48.4659"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, et al. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016;22:44\u201353. [PMID: 26311725 DOI: 10.1158\/1078-0432.CCR-15-1127]","DOI":"10.1158\/1078-0432.ccr-15-1127"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Matrone A, Prete A, Nervo A, Ragni A, Agate L, Molinaro E, et al. Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer. J Endocrinol Invest. 2021;44:2139\u201351. [PMID: 33594641 DOI: 10.1007\/s40618-020-01491-3]","DOI":"10.1007\/s40618-021-01592-7"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020;383:825\u201335. [PMID: 32846061 PMCID: PMC10777663 DOI: 10.1056\/NEJMoa2005651]","DOI":"10.1056\/NEJMoa2005651"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, et al. Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. J Clin Oncol. 2024;42:3187\u201395. [PMID: 39094065 PMCID: PMC11404750 DOI: 10.1200\/JCO.23.02503]","DOI":"10.1200\/jco.23.02503"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, et al.; LIBRETTO-531 Trial Investigators. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023;389:1851\u201361. [PMID: 37870969 DOI: 10.1056\/NEJMoa2309719]","DOI":"10.1056\/nejmoa2309719"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol. 2021;9:491\u2013501. [PMID: 34118198 DOI: 10.1016\/S2213-8587(21)00120-0]","DOI":"10.1016\/s2213-8587(21)00120-0"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, et al. Pralsetinib in Patients with Advanced\/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024;34:26\u201340. [PMID: 38009200 DOI: 10.1089\/thy.2023.0363]","DOI":"10.1089\/thy.2023.0363.correx"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Rao SN, Smallridge RC. Anaplastic thyroid cancer: An update. Best Pract Res Clin Endocrinol Metab. 2023;37:101678. [PMID: 35668021 DOI: 10.1016\/j.beem.2022.101678]","DOI":"10.1016\/j.beem.2022.101678"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Maniakas A, Zafereo M, Cabanillas ME. Anaplastic Thyroid Cancer: New Horizons and Challenges. Endocrinol Metab Clin North Am. 2022;51:391\u2013401. [PMID: 35662448 DOI: 10.1016\/j.ecl.2021.11.020]","DOI":"10.1016\/j.ecl.2021.11.020"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, et al. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol. 2024;10:1264\u201371. [PMID: 38990526 DOI: 10.1001\/jamaoncol.2024.2133]","DOI":"10.1001\/jamaoncol.2024.2133"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Yang SR, Tsai MH, Hung CJ, Peng SL, Chiu NT, Huang YH, et al. Anaplastic Thyroid Cancer Successfully Treated With Radiation and Immunotherapy: A Case Report. AACE Clin Case Rep. 2021;7:299\u2013302. [PMID: 34522768 PMCID: PMC8426608 DOI: 10.1016\/j.aace.2021.03.003]","DOI":"10.1016\/j.aace.2021.03.003"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Romei C, Tacito A, Molinaro E, Piaggi P, Cappagli V, Pieruzzi L, et al. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience. Oncol Lett. 2018;15:9174\u201382. [PMID: 29805648 PMCID: PMC5958691 DOI: 10.3892\/ol.2018.8470]","DOI":"10.3892\/ol.2018.8470"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, et al. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018;24:3059\u201368. [PMID: 29615459 PMCID: PMC6030480 DOI: 10.1158\/1078-0432.CCR-18-0373]","DOI":"10.1158\/1078-0432.ccr-18-0373"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005;103:2261\u20138. [PMID: 15880523 DOI: 10.1002\/cncr.21073]","DOI":"10.1002\/cncr.21073"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Minna E, Brich S, Todoerti K, Pilotti S, Collini P, Bonaldi E, et al. Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. Cancers (Basel). 2020;12:112. [PMID: 31906302 PMCID: PMC7016563 DOI: 10.3390\/cancers12010112]","DOI":"10.3390\/cancers12010112"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, et al. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019;29:1036\u201343. [PMID: 31319771 PMCID: PMC6707029 DOI: 10.1089\/thy.2019.0133]","DOI":"10.1089\/thy.2019.0133"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001;130:1028\u201334. [PMID: 11742333 DOI: 10.1067\/msy.2001.118266]","DOI":"10.1067\/msy.2001.118266"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Navas Moreno V, Sebasti\u00e1n Valles F, Lahera Vargas M, Hern\u00e1ndez Mar\u00edn B, Carrillo L\u00f3pez E, Marazuela M, et al. Neoadjuvant Treatment in Locally Advanced Thyroid Carcinoma. J Clin Med. 2024;13:5769. [PMID: 39407830 PMCID: PMC11477333 DOI: 10.3390\/jcm13195769]","DOI":"10.3390\/jcm13195769"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Barbaro D, Forleo R, Profilo MA, Lapi P, Giani C, Torregrossa L, et al. Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report. Front Endocrinol (Lausanne). 2024;15:1389294. [PMID: 39045273 PMCID: PMC11263007 DOI: 10.3389\/fendo.2024.1389294]","DOI":"10.3389\/fendo.2024.1389294"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, et al. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid. 2023;33:484\u201391. [PMID: 36762947 PMCID: PMC10122263 DOI: 10.1089\/thy.2022.0504]","DOI":"10.1089\/thy.2022.0504"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, et al. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid. 2018;28:945\u201351. [PMID: 29742974 PMCID: PMC6425982 DOI: 10.1089\/thy.2018.0060]","DOI":"10.1089\/thy.2018.0060"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Song Y, Zhang Y, Bai Y, Wang T, Xu G, Ma X, et al. Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study. Oral Oncol. 2024;159:107067. [PMID: 39395384 DOI: 10.1016\/j.oraloncology.2024.107067]","DOI":"10.1016\/j.oraloncology.2024.107067"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al.; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:271\u201382. [PMID: 31838007 PMCID: PMC7461630 DOI: 10.1016\/S1470-2045(19)30691-6]","DOI":"10.1016\/j.jtho.2019.08.611"},{"key":"ref59","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) v5. 0. Cancer Ther Eval Progr. 2017;155."},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Barbaro D, Lapi P, Viacava P, Torregrossa L. Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe. BMJ Case Rep. 2020;13:e236934. [PMID: 33370973 PMCID: PMC7757514 DOI: 10.1136\/bcr-2020-236934]","DOI":"10.1136\/bcr-2020-236934"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Iwasaki H, Toda S, Suganuma N, Murayama D, Nakayama H, Masudo K. Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer. Mol Clin Oncol. 2020;12:138\u201343. [PMID: 31929884 PMCID: PMC6951241 DOI: 10.3892\/mco.2019.1964]","DOI":"10.3892\/mco.2019.1964"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D, et al. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Clin Cancer Res. 2018;24:1296\u2013304. [PMID: 29358502 DOI: 10.1158\/1078-0432.CCR-17-2439]","DOI":"10.1158\/1078-0432.c.6524373.v1"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Yang S, Ji D, Xue F, Chen T, Wang Y, Ji Q. Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma. Cancer Rep (Hoboken). 2023;6:e1770. [PMID: 36535914 PMCID: PMC9875607 DOI: 10.1002\/cnr2.1770]","DOI":"10.1002\/cnr2.1770"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Molinaro E, Campopiano MC, Pieruzzi L, Matrone A, Agate L, Bottici V, et al. Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. J Clin Endocrinol Metab. 2020;105:e172\u201380. [PMID: 31652318 PMCID: PMC8105780 DOI: 10.1210\/clinem\/dgz113]","DOI":"10.1210\/clinem\/dgz113"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, et al. Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. JAMA Otolaryngol Head Neck Surg. 2017;143:1015\u201320. [PMID: 28859191 PMCID: PMC5710258 DOI: 10.1001\/jamaoto.2017.1442]","DOI":"10.1001\/jamaoto.2017.1442"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Sanabria A, Ferraz C, Ku CHC, Padovani R, Palacios K, Paz JL, et al. Implementing active surveillance for low-risk thyroid carcinoma into clinical practice: collaborative recommendations for Latin America. Arch Endocrinol Metab. 2024;68:e230371. [PMID: 39420909 PMCID: PMC11192484 DOI: 10.20945\/2359-4292-2023-0371]","DOI":"10.20945\/2359-4292-2023-0371"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1\u2013133. [PMID: 26462967 PMCID: PMC4739132 DOI: 10.1089\/thy.2015.0020]","DOI":"10.1089\/thy.2015.0020"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29:461\u201370. [PMID: 30900516 DOI: 10.1089\/thy.2018.0597]","DOI":"10.1089\/thy.2018.0597"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Gay S, Monti E, Trambaiolo Antonelli C, Mora M, Spina B, Ansaldo G, et al. Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma. Future Oncol. 2019;15:13\u20139. [PMID: 31385546 DOI: 10.2217\/fon-2019-0099]","DOI":"10.2217\/fon-2019-0099"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Alshehri K, Alqurashi Y, Merdad M, Samargandy S, Daghistani R, Marzouki H. Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review. Cancer Rep (Hoboken). 2022;5:e1466. [PMID: 34105309 PMCID: PMC8842697 DOI: 10.1002\/cnr2.1466]","DOI":"10.1002\/cnr2.1466"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Valerio L, Giani C, Agate L, Molinaro E, Viola D, Bottici V, et al. Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer. Eur Thyroid J. 2021;10:399\u2013407. [PMID: 34540710 PMCID: PMC8406256 DOI: 10.1159\/000514182]","DOI":"10.1159\/000514182"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Pitoia F, Abelleira E, Rom\u00e1n-Gonz\u00e1lez A, Danilovic DLS, Scheffel RS, Maia AL, et al. Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience. Thyroid. 2024;34:949\u201352. [PMID: 38757613 DOI: 10.1089\/thy.2024.0090]","DOI":"10.1089\/thy.2024.0090"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Tsuboi M, Takizawa H, Aoyama M, Tangoku A. Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: A case report. Int J Surg Case Rep. 2017;41:89\u201392. [PMID: 29055877 PMCID: PMC5651555 DOI: 10.1016\/j.ijscr.2017.10.010]","DOI":"10.1016\/j.ijscr.2017.10.010"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Stewart KE, Strachan MWJ, Srinivasan D, MacNeill M, Wall L, Nixon IJ. Tyrosine Kinase Inhibitor Therapy in Locally Advanced Differentiated Thyroid Cancer: A Case Report. Eur Thyroid J. 2019;8:102\u20137. [PMID: 31192150 PMCID: PMC6514483 DOI: 10.1159\/000494880]","DOI":"10.1159\/000494880"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Iwasaki H, Toda S, Ito H, Nemoto D, Murayama D, Okubo Y, et al. A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy. Case Rep Endocrinol. 2020;2020:6438352. [PMID: 32455032 PMCID: PMC7238324 DOI: 10.1155\/2020\/6438352]","DOI":"10.1155\/2020\/6438352"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Danilovic DLS, Castro G Jr, Roitberg FSR, Vanderlei FAB, Bonani FA, Freitas RMC, et al. Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. Arch Endocrinol Metab. 2018;62:370\u20135. [PMID: 29791660 PMCID: PMC10118781 DOI: 10.20945\/2359-3997000000046]","DOI":"10.20945\/2359-3997000000046"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Nava CF, Scheffel RS, Cristo AP, Ferreira CV, Weber S, Zanella AB, et al. Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma. Front Endocrinol (Lausanne). 2019;10:712. [PMID: 31695679 PMCID: PMC6817485 DOI: 10.3389\/fendo.2019.00712]","DOI":"10.3389\/fendo.2019.00712"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Huang NS, Wei WJ, Xiang J, Chen JY, Guan Q, Lu ZW, et al. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial. Thyroid. 2021;31:1808\u201313. [PMID: 34610756 DOI: 10.1089\/thy.2021.0307]","DOI":"10.1089\/thy.2021.0307"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Chen JY, Huang NS, Wei WJ, Hu JQ, Cao YM, Shen Q, et al. The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study. Ann Surg Oncol. 2023;30:7172\u201380. [PMID: 37543550 DOI: 10.1245\/s10434-023-14031-z]","DOI":"10.1245\/s10434-023-14031-z"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Matrone A, Gambale C, Prete A, Cappagli V, Lorusso L, Bottici V, et al. Systemic treatment of advanced, metastatic, medullary thyroid carcinoma. J Cancer Metastasis Treat. 2021;7:23. [DOI: 10.20517\/2394-4722.2021.47]","DOI":"10.20517\/2394-4722.2021.47"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al.; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567\u2013610. [PMID: 25810047 PMCID: PMC4490627 DOI: 10.1089\/thy.2014.0335]","DOI":"10.1089\/thy.2014.0335"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Matrone A, Gambale C, Prete A, Elisei R. Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine. Front Endocrinol (Lausanne). 2022;13:864253. [PMID: 35422765 PMCID: PMC9004483 DOI: 10.3389\/fendo.2022.864253]","DOI":"10.3389\/fendo.2022.864253"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Ciampi R, Ramone T, Romei C, Casalini R, Matrone A, Prete A, et al. NF1 Gene Inactivation Acts as Tumor Driver in RET\/RAS Negative Medullary Thyroid Carcinomas. Eur J Endocrinol. 2023:lvad051. [PMID: 37216402 DOI: 10.1093\/ejendo\/lvad051]","DOI":"10.1093\/ejendo\/lvad051"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Ciampi R, Romei C, Ramone T, Prete A, Tacito A, Cappagli V, et al. Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. iScience. 2019;20:324\u201336. [PMID: 31605946 PMCID: PMC6817656 DOI: 10.1016\/j.isci.2019.09.030]","DOI":"10.1016\/j.isci.2019.09.030"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Romei C, Tacito A, Molinaro E, Agate L, Bottici V, Viola D, et al. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? Clin Endocrinol (Oxf). 2015;82:892\u20139. [PMID: 25440022 DOI: 10.1111\/cen.12686]","DOI":"10.1111\/cen.12686"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Matrone A, Elisei R. Insights into highly selective RET inhibitors in medullary thyroid cancer. Curr Opin Endocr Metab Res. 2024;35:100521. [DOI: 10.1016\/j.coemr.2024.100521]","DOI":"10.1016\/j.coemr.2024.100521"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Romei C, Casella F, Tacito A, Bottici V, Valerio L, Viola D, et al. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. J Med Genet. 2016;53:729\u201334. [PMID: 27468888 DOI: 10.1136\/jmedgenet-2016-103833]","DOI":"10.1136\/jmedgenet-2016-103833"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zheng WH, Zhou SH, Gu JL, Yu Q, Zhu YZ, et al. Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives. Cell Commun Signal. 2024;22:460. [PMID: 39342195 PMCID: PMC11439284 DOI: 10.1186\/s12964-024-01837-x]","DOI":"10.1186\/s12964-024-01837-x"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Adashek JJ, Desai AP, Andreev-Drakhlin AY, Roszik J, Cote GJ, Subbiah V. Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers. Mol Cancer Ther. 2021;20:1769\u201376. [PMID: 34493590 PMCID: PMC8492504 DOI: 10.1158\/1535-7163.MCT-21-0329]","DOI":"10.1158\/1535-7163.mct-21-0329"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Gigliotti BJ, Brooks JA, Wirth LJ. Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma. Mol Cell Endocrinol. 2024;592:112295. [PMID: 38871174 DOI: 10.1016\/j.mce.2024.112295]","DOI":"10.1016\/j.mce.2024.112295"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, et al. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021;43:E7\u201312. [PMID: 33169506 PMCID: PMC7756223 DOI: 10.1002\/hed.26527]","DOI":"10.1002\/hed.26527"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, et al. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid. 2023;33:129\u201332. [PMID: 36503246 DOI: 10.1089\/thy.2022.0506]","DOI":"10.1089\/thy.2022.0506"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"De Leo S, Trevisan M, Re Sart\u00f2 GV, Moneta C, Pirovano M, Colombo C, et al. Letter to the Editor: Tumor Lysis Syndrome During Selpercatinib Treatment in a Patient with Medullary Thyroid Cancer. Thyroid. 2023;33:1130\u20132. [PMID: 37463111 DOI: 10.1089\/thy.2023.0214]","DOI":"10.1089\/thy.2023.0214"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Grasic Kuhar C, Lozar T, Besic N, Music Marolt M. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia. Adv Ther. 2021;38:5684\u201399. [PMID: 34674146 DOI: 10.1007\/s12325-021-01940-2]","DOI":"10.1007\/s12325-021-01940-2"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Cleary JM, Sadow PM, Randolph GW, Palmer EL, Lynch TP, Nikiforov YE, et al. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J Clin Oncol. 2010;28:e390\u20132. [PMID: 20567012 DOI: 10.1200\/JCO.2009.27.4225]","DOI":"10.1200\/jco.2009.27.4225"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Golingan H, Hunis B, Golding AC, Bimston DN, Harrell RM. Neoadjuvant Lenvatinib in Advanced Unresectable Medullary Thyroid Carcinoma: A Case Report. AACE Clin Case Rep. 2019;6:e73\u20138. [PMID: 32524015 PMCID: PMC7282158 DOI: 10.4158\/ACCR-2019-0365]","DOI":"10.4158\/accr-2019-0365"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Gugenheim J, Crovetto A, Petrucciani N. Neoadjuvant therapy for pancreatic cancer. Updates Surg. 2022;74:35\u201342. [PMID: 34628591 PMCID: PMC8502083 DOI: 10.1007\/s13304-021-01186-1]","DOI":"10.1007\/s13304-021-01186-1"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021;39:1485\u2013505. [PMID: 33507815 PMCID: PMC8274745 DOI: 10.1200\/JCO.20.03399]","DOI":"10.1200\/jco.20.03399"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Smith HG, Nilsson PJ, Shogan BD, Harji D, Gambacorta MA, Romano A, et al. Neoadjuvant treatment of colorectal cancer: comprehensive review. BJS Open. 2024;8:zrae038. [PMID: 38747103 PMCID: PMC11094476 DOI: 10.1093\/bjsopen\/zrae038]","DOI":"10.1093\/bjsopen\/zrae038"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Matrone A, De Napoli L, Torregrossa L, Aghababyan A, Papini P, Ambrosini CE, et al. Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses. Front Oncol. 2022;12:854755. [PMID: 35463338 PMCID: PMC9022105 DOI: 10.3389\/fonc.2022.854755]","DOI":"10.3389\/fonc.2022.854755"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Clifton-Bligh RJ. Mechanisms of resistance to RET-directed therapies. Endocr Relat Cancer. 2025;32:e240224. [PMID: 39655713 PMCID: PMC11798414 DOI: 10.1530\/ERC-24-0224]","DOI":"10.1530\/ERC-24-0224"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Subbiah V, Gouda MA, Iorgulescu JB, Dadu R, Patel K, Sherman S, et al. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ Precis Oncol. 2024;8:62. [PMID: 38438731 PMCID: PMC10912412 DOI: 10.1038\/s41698-024-00563-4]","DOI":"10.1038\/s41698-024-00563-4"}],"container-title":["Exploration of Targeted Anti-tumor Therapy"],"original-title":[],"link":[{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T01:28:26Z","timestamp":1739496506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":103,"URL":"https:\/\/doi.org\/10.37349\/etat.2025.1002291","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3114"],"issn-type":[{"value":"2692-3114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"2024-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-1-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-2-13","order":2,"name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1002291"}}